Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
Authors' conclusion
This study revealed a high heterogeneity in adalimumab exposure in PRD. Adalimumab exposure tended to be higher with methotrexate co-treatment compared to adalimumab monotherapy although differences were not statistically significant.
Study context
- Population
- Patients aged 2–18 years with pediatric rheumatic diseases (JIA 71.4%, non-infectious uveitis 25%, chronic recurrent multifocal osteomyelitis 3.6%)completed the study
- Participants
- 28 patients
- Exposure
- Adalimumab plus MTX vs adalimumab alone
- GA-Mn = 14
- GAn = 14reference
- Outcome
- Log-normalized adalimumab Cmin (10-14 days post-dose), GA-M vs GA
Methodological detailstwo-centre
- Two-centre
Main finding
As reported in the abstract
Adalimumab Cmin
- Median Cmin statistically not different between GA-M and GA
- p = 0.3
Observational data: associations, not effects.
Further findings
Cmin ≥ 8 mg/L (upper limit RA)
Duration of adalimumab exposure at first study visit
P = 0.8
Range of Cmin values overall
- Wide range of Cmin values
- 0.5 to 26 mg/L
Original publication
Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases. Pediatr Rheumatol Online J. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →